ARVN oversold will bounce back within 5 days NASDAQ:ARVN [/symbol Oversold, resistance/old support $40,44,50. first Pt:40 within a week IMO. analysts pt : $66
Key stats
Market capitalization
1.409BUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−5.31USD
About Arvinas, Inc
ISIN
US04335A1051
Sector
Health Technology
Industry
Biotechnology
Website
arvinas.com
CEO
John G. Houston
Headquarters
New Haven
Employees
415
Founded
2013
Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
0
Revenue
0